Sign in
WithdrawnPhase 1/2

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Key facts

Who runs it
Chongqing Precision Biotech Co., Ltd
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
20 Feb 2020
Ended
30 Apr 2024
Type of study
Interventional
Treatments tested
  • CEA CAR-T cells
Record updated
10 July 2026
Why it stopped
The sponsor requested to terminate the study.

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • No gender limitation, age 18-75 years old (including boundary value)
  • Late, metastatic, or recurrent malignant tumors that have received at least first-line standard treatment failure (progressive or intolerable disease, such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.) or lack effective treatment, and the tumor CEA positive expression (tumor CEA positive or serum CEA level> 50ng / ml confirmed by histology or pathology)
  • There are measurable and assessable lesions: the diameter of the lesion under CT or MRI scan is greater than 0.5cm
  • The expected survival time is more than 12 weeks
  • KPS≥60
  • No serious mental disorders
  • The functions of important organs are basically normal:; Blood routine: white blood cells> 2.0 × 10\^9 / L, neutrophils> 0.8 × 10\^9 / L, lymphocytes> 0.5 × 10\^9 / L, platelets> 50 × 10\^9 / L, hemoglobin> 90g / L; Cardiac function: cardiac ultrasound indicates that the cardiac ejection fraction is ≥50%, and there is no obvious abnormality on the electrocardiogram; Renal function: serum creatinine and urea nitrogen ≤3.0 × ULN; Liver function: ALT and AST ≤5.0 × ULN; total bilirubin ≤3.0 × ULN; Blood oxygen saturation> 92%
  • There are no other serious diseases that conflict with this plan (such as autoimmune diseases, immunodeficiency, organ transplantation)
  • There are no contraindications for apheresis or intravenous blood collection or other cell collection
  • The patient or his guardian agrees to participate in this clinical trial and sign the ICF, indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the study

Who cannot take part

  • Have received CAR-T treatment or other genetically modified cell treatment before screening
  • Participated in other clinical studies within 1 month before screening
  • Received the following anti-tumor treatment before screening: received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except for those who have confirmed disease progression after treatment
  • Have received live attenuated vaccine within 4 weeks before screening
  • Cerebrovascular accident or seizure occurred within 6 months before signing the ICF
  • Suffering from any of the following heart diseases:; New York Heart Association (NYHA) stage III or IV congestive heart failure; Myocardial infarction occurred or received coronary artery bypass graft (CABG) ≤6 months before enrollment; Clinically significant ventricular arrhythmias, or history of syncope of unknown cause (except for conditions caused by vasovagal or dehydration); Severe cardiac insufficiency, severe heart valve disease and other cardiovascular system diseases
  • There are active infections or uncontrollable infections requiring systemic treatment within 2 weeks before screening
  • Active autoimmune diseases
  • Suffering from other malignant tumors, in addition to fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection
  • Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive
  • Suffering from chronic enteritis and / or intestinal obstruction
  • Women who are pregnant or breastfeeding
  • The situation that other researchers think is not suitable for participating in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.

The group in the trial

  • CEA+ CAR-TTreatment being tested

    CAR-T cell reinfusion is carried out in 1\~3 times

    Treatment: CEA CAR-T cells

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer
Record updated
10 July 2026